Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Seagen Inc.
Mayo Clinic
Kivu Bioscience Inc.
Eastern Cooperative Oncology Group
Eli Lilly and Company
Neonc Technologies, Inc.
ViroMissile, Inc.
Rutgers, The State University of New Jersey
Terremoto Biosciences Inc.
Bristol-Myers Squibb
Sichuan Enray Pharmaceutical Sciences Company
AstraZeneca
Tizona Therapeutics, Inc
Genentech, Inc.
The Institute of Molecular and Translational Medicine, Czech Republic
Normunity AccelCo, Inc.
Eli Lilly and Company
University of Colorado, Denver
MacroGenics
Institut Curie
Theravectys S.A.
Karolinska University Hospital
SystImmune Inc.
Daiichi Sankyo
Eli Lilly and Company
Adela, Inc
Radiopharm Theranostics, Ltd
Innate Pharma
OncoNano Medicine, Inc.
Tanabe Pharma America, Inc.
Therorna
DualityBio Inc.
AstraZeneca
Massive Bio, Inc.
Chongqing Precision Biotech Co., Ltd
LigaChem Biosciences, Inc.
Washington University School of Medicine
Institut Claudius Regaud
Travera Inc
Nurix Therapeutics, Inc.
Jonsson Comprehensive Cancer Center
The Netherlands Cancer Institute
Yuhan Corporation
Medicenna Therapeutics, Inc.
Marengo Therapeutics, Inc.
ModeX Therapeutics, An OPKO Health Company
Cancer Research UK
UNICANCER
Precision Biologics, Inc